Clinical Effect of Full-course Intravenous Azithromycin Comprehensive Regimen in the Treatment of Streptococcus pneumoniae Pneumonia in Children

doi:10.16458/j.cnki.1007-0893.2025.11.020

Abstract：Objective: To investigate the clinical effect of full-course intravenous azithromycin comprehensive regimen in the treatment of Streptococcus pneumoniae pneumonia in children. Methods: A total of 98 children with Streptococcus pneumoniae pneumonia treated at Henan Provincial Children's Hospital from January 2022 to January 2024 were selected as the study subjects and divided into control group and observation group according to different treatment regimens, with 49 cases in each group. The control group received conventional comprehensive drug therapy, while the observation group received full-course intravenous comprehensive drug therapy. The time for main symptoms to subside, pulmonary function indicators before and after treatment, serum inflammatory factor levels, and incidence of adverse reactions were compared between the two groups. Results: The time for fever, cough, lung rales, and lung shadows to subside in the observation group was shorter than that in the control group, with statistically significant differences (P<0.05). After treatment, the peak expiratory flow rate (PEF), forced expiratory volume in the first second (FEV1), vital capacity (FVC), and maximum expiratory flow at 50% vital capacity (MEF50) in the observation group were higher than those in the control group, with statistically significant differences (P<0.05). After treatment, the serum levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and procalcitonin (PCT) in the observation group were lower than those in the control group, with statistically significant differences (P<0.05). There was no statistically significant difference in the overall incidence of adverse reactions between the two groups (P>0.05). Conclusion: The full-course intravenous azithromycin comprehensive regimen is effective in treating children with Streptococcus pneumoniae pneumonia, which can rapidly alleviate clinical symptoms, promote recovery of pulmonary function, and inhibit inflammatory response without increasing adverse reactions.